Core Viewpoint - Kintor Pharmaceutical (02171.HK) has signed a strategic cooperation agreement with Shanghai Jinkong Enterprise Development to invest up to 370 million yuan in building a CAR-T cell therapy product commercialization production base in Shanghai's Jinshan District, aligning with the commercialization process of multiple CAR-T products [1][2]. Group 1: Investment and Production Base - The total investment for the new CAR-T drug production base is capped at 370 million yuan, with the construction managed by Shanghai Jinkong [1]. - The investment will be executed through a phased payment model, allowing Kintor to retain cash flow for core R&D and new drug promotion [3]. - The construction is expected to take 14 months, with Kintor making quarterly service fee payments during the initial years [3]. Group 2: Product Development and Market Potential - Kintor's CAR-T product, Shurui Kiorunai, is currently under review for market approval and is the first entity-targeting CAR-T product to submit a New Drug Application in China [2]. - The product targets Claudin18.2 positive advanced gastric/esophageal junction adenocarcinoma, with clinical trial results showing superior efficacy compared to existing therapies [2]. - The market for gastric cancer treatment is significant, with 358,700 new cases and 260,400 deaths reported in 2022 in China, indicating a high demand for effective therapies [2]. Group 3: Financial Performance - Kintor expects a significant reduction in net losses, projecting a loss of no more than 120 million yuan for the reporting period, down from 798 million yuan in the previous year [4]. - The reduction in losses is attributed to increased commercialization revenue from the existing product, Zewokiorunai, and decreased R&D expenditures for both Zewokiorunai and Shurui Kiorunai [4]. - As of June 30, 2025, Kintor reported cash and bank balances of approximately 1.261 billion yuan, indicating sufficient cash flow until 2028 without considering future inflows [3].

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

此举紧密配合公司多款CAR-T细胞治疗产品的商业化进程，包括已上市的赛恺泽®及处于新药上市申请阶段的实体瘤 CAR-T细胞治疗产品舒瑞基奥仑赛注射液（研发代号"CT041"，拟定商品名"恺力美™"），并为多款通用型CAR-T细 胞治疗产品（如CT0596、CT1190B等）的未来量产奠定基础。在此背景下，提升符合国际标准的CAR-T细胞治疗产能 成为支撑多个产品商业化落地及增强全球竞争力的核心举措。此次交易中，本公司早期无需进行大额资本开支，有效 保留了宝贵现金流用于核心研发与市场拓展。同时，回购机制确保本公司在长期运营后可完整取得资产控制权，既维 持了生产稳定性，又强化了资产布局的灵活性。 （科济药业公众号） 2月13日，科济药业发布公告称，，公司透过其间接全资附属公司上海恺兴诊断技术有限公司，与上海市金山区湾区 高新区的重要平台企业——上海金工企业发展有限公司签署战略合作协议，总投资额不超过人民币3.7亿元，将在上海 市金山区建设先进的CAR-T细胞治疗产品商业化生产基地。 ...

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building an advanced CAR-T cell therapy product commercialization production base in Shanghai, aligning with its commercialization process for multiple CAR-T products [1] Group 1: Investment and Development - The total investment for the new production base is capped at RMB 370 million, which will support the commercialization of existing and upcoming CAR-T cell therapy products [1] - The production base will facilitate the commercialization of the already launched product, Sai Kaize, and the new drug application stage product, Shu Ru Ji Ao Lun Sai injection (tentative name: Kai Li Mei TM) [1] - The investment strategy allows the company to avoid significant capital expenditures early on, preserving cash flow for core R&D and market expansion [1] Group 2: Strategic Importance - The collaboration is seen as a core initiative to enhance CAR-T cell therapy production capacity that meets international standards, crucial for the commercialization of multiple products and strengthening global competitiveness [1] - The agreement reflects the company's robust financial planning and deep engagement in the CAR-T cell therapy industry ecosystem, aligning with national and local biopharmaceutical industry policies [1] - This strategic partnership is expected to solidify the company's leading position in the global CAR-T cell therapy field and create long-term value for shareholders [1]

格隆汇2月13日丨科济药业-B(02171.HK)发布公告，2026年2月12日，科济药业控股有限公司透过其间接 全资附属公司上海恺兴诊断技术，与上海市金山区湾区高新区的重要平台企业——上海金工企业发展签 署战略合作协议，总投资额不超过人民币3.7亿元，将在上海市金山区建设先进的CAR-T细胞治疗产品 商业化生产基地。 此举紧密配合公司多款CAR-T细胞治疗产品的商业化进程，包括已上市的赛恺泽®及处于新药上市申请 阶段的实体瘤CAR-T细胞治疗产品舒瑞基奥仑赛注射液(拟定商品名：恺力美TM)，并为多款通用型 CAR-T细胞治疗产品(如CT0596、CT1190B等)的未来量产奠定基础。在此背景下，提升符合国际标准的 CAR-T细胞治疗产能成为支撑多个产品商业化落地及增强全球竞争力的核心举措。此次交易公司早期无 需进行大额资本开支，有效保留了宝贵现金流用于核心研发与市场拓展。同时，回购机制确保本公司在 长期运营后可完整取得资产控制权，既维持了生产稳定性，又强化了资产布局的灵活性。 总体来看，此次合作彰显了公司稳健的财务规划和对CAR-T细胞治疗产业生态系统的深度布局，也表明 该项目高度契合国家及地方的生物医药产 ...

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 須予披露交易— 訂立戰略合作協議 戰略合作協議 董事會欣然宣佈，於2026年2月12日（交易時段後）科濟藥業控股有限公司透 過其間接全資附屬公司上海愷興診斷技術，與上海市金山區灣區高新區的重要 平台企業——上海金工企業發展簽署戰略合作協議，總投資額不超過人民幣 37,000萬元，將在上海市金山區建設先進的CAR-T細胞治療產品商業化生產基 地。此舉緊密配合本公司多款CAR-T細胞治療產品的商業化進程，包括已上市 的賽愷澤®及處於新藥上市申請階段的實體瘤CAR-T細胞治療產品舒瑞基奧侖 賽注射液（擬定商品名：愷力美TM），並為多款通用型CAR-T細胞治療產品（如 CT0596、CT1190B等）的未來量產奠定基礎。在此背景下，提升符合國際標準 的CAR-T細胞治療產能成為支撐多個產品商業 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | 本月 ...

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]

Core Viewpoint - The company expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of Zewokaiolun Injection and the acceptance of the NDA for Shurukiaolun Injection by the NMPA [1] Financial Performance - The net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zewokaiolun Injection in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in R&D expenses for both Zewokaiolun Injection and Shurukiaolun Injection [1]